Medizen Humancare Inc Co., Ltd.

As of December 31, 2025, Medizen Humancare Inc Co., Ltd. carries a market capitalization of 5.12B, placing it among publicly traded companies globally. Its enterprise value stands at 5.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Medizen Humancare Inc Co., Ltd. has 3.01M shares outstanding.

As of December 31, 2025, Medizen Humancare Inc Co., Ltd. trades at a trailing price-to-earnings ratio of 15.78. The price-to-sales ratio is 1.16, and the price-to-book ratio stands at -0.41.

These figures are as of December 31, 2025. The EV/Sales ratio of 1.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Medizen Humancare Inc Co., Ltd. trades at an EV/FCF ratio of 75.13, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 5.60B versus a market cap of 5.12B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Medizen Humancare Inc Co., Ltd. maintains a current ratio of 0.17, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -5.22, indicating conservative leverage, while an interest coverage ratio of -12.21 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) stands at 10.19, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -3.16, pointing to unprofitable operations over the period. Inventory turnover of 4.09 indicates how many times Medizen Humancare Inc Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Medizen Humancare Inc Co., Ltd.'s stock has declined approximately 29.73% over the past 52 weeks. The 50-day moving average sits at 2,036.76, while the 200-day moving average is 2,152.85.

Over the twelve months ended December 31, 2025, Medizen Humancare Inc Co., Ltd. generated 4.42B in revenue and converted that into 324.79M in net income, yielding earnings per share of 104.17. EBITDA reached -675.00M, while operating income came in at -1.16B.

As of December 31, 2025, Medizen Humancare Inc Co., Ltd. holds 177.74M in cash and equivalents against 651.26M in total debt, resulting in a net debt position of 263.51M. Total book value stands at -12.48B, with working capital of -12.51B providing operational flexibility.

Medizen Humancare Inc Co., Ltd. produced 115.02M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -95.79M in capital expenditures, free cash flow totaled 19.23M - equivalent to 6.38 per share.

Over the twelve months ended December 31, 2025, Medizen Humancare Inc Co., Ltd. posted a gross margin of 28.15, reflecting its pricing power and cost economics. The operating margin of -26.19 and net profit margin of 7.34 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield stands at 0.36, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.97, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medizen Humancare Inc Co., Ltd. shareholders.

As of December 31, 2025, Medizen Humancare Inc Co., Ltd. has an Altman Z-Score of -17.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.